NCT00638716View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

CJC-1134-PC

1.5 or 2.0 mg CJC-1134-PC

DRUG

Placebo

Placebo

Trial Locations (1)

H2X 3Y8

ConjuChem Biotechnologies Inc., Montreal

Sponsors

Lead Sponsor

ConjuChem
All Listed Sponsors
lead

ConjuChem

INDUSTRY